Organization (Industry)
BioNTech SE
ClinicalTrials.gov lists BioNTech SE as lead sponsor of 84 trials, counting the companies grouped under it. BioNTech SE itself has 310 active development programs and 21 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 14 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 18 in 2026 and about 19 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo BioNTech SE, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers BioNTech SE and 5 companies grouped under it: 84 lead-sponsored trials (74 its own, 10 in the grouped companies) and 5 legal-entity registrations (3 its own, 2 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (5)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| BioNTech US Inc. | 4 | 0 |
| BioNTech Research & Development, Inc. | 3 | 0 |
| BioNTech Diagnostics GmbH | 2 | 0 |
| BioNTech Cell & Gene Therapies GmbH | 1 | 0 |
| JPT Peptide Technologies (Germany) | 0 | 2 |
Disease areas (49)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| COVID-19 | 29 |
| Lung Neoplasms | 20 |
| Carcinoma, Non-Small-Cell Lung | 16 |
| Breast Neoplasms | 9 |
| Colorectal Neoplasms | 8 |
Showing 5 of 49 disease areas.
Trials by start year as sponsor or collaborator (13)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 14 |
| 2025 | 23 |
| 2024 | 9 |
| 2023 | 15 |
| 2022 | 15 |
| 2021 | 16 |
| 2020 | 7 |
| 2019 | 3 |
| 2018 | 1 |
| 2017 | 2 |
Showing 10 of 13 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 26 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 43 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (310)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Pumitamig | Lung Neoplasms | Phase 3 | 5 |
| CARBOPLATIN | Lung Neoplasms | Phase 3 | 5 |
| ETOPOSIDE | Lung Neoplasms | Phase 3 | 3 |
| ETOPOSIDE | Small Cell Lung Carcinoma | Phase 3 | 3 |
| CARBOPLATIN | Small Cell Lung Carcinoma | Phase 3 | 3 |
Showing 5 of 310 active programs.
Approved assets (21)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| BNT162B2 | 16 |
| BNT162b2 Vaccine | 2 |
| Tdap Vaccine | 1 |
| CARBOPLATIN | 7 |
| (nab)-paclitaxel | 5 |
Showing 5 of 21 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 70% hit target (n=47) | 35% on time (n=43) |
Journals published in (32)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The New England journal of medicine | 8 |
| Nature | 5 |
| Vaccine | 5 |
| Science immunology | 3 |
| Vaccines | 3 |
Showing 5 of 32 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 103 | 58 | 2025-11-04 |
SEC-reported annual financials (10)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 3,237,563,811 | -1,281,646,136 | 2,374,559,415 |
| 2024 | 2,976,671,569 | -719,850,094 | 2,439,029,134 |
| 2023 | 4,132,618,202 | 1,006,696,704 | 1,929,529,069 |
| 2022 | 18,202,271,324 | 9,920,367,207 | 1,616,171,075 |
| 2021 | 22,437,672,011 | 12,169,646,944 | 1,122,315,169 |
| 2020 | 550,004,454 | 17,333,750 | 735,544,003 |
| 2019 | 121,782,823 | -200,952,873 | 253,994,563 |
| 2018 | 149,949,700 | -56,726,415 | 168,127,024 |
| 2017 | 69,405,252 | -96,843,752 | 96,332,209 |
| 2016 | not reported | not reported | not reported |
Financing and grant events (81)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-07 | Other financing | not disclosed | Sec extracted |
| 2026-01-06 | Other financing | not disclosed | Sec extracted |
| 2025-12-18 | Other financing | not disclosed | Sec extracted |
| 2025-12-03 | Other financing | not disclosed | Sec extracted |
| 2025-11-26 | Other financing | not disclosed | Sec extracted |
Showing 5 of 81 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (16)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Duality Biotherapeutics, Inc. (China) | Co sponsors trial with | 4 |
| MediLink Therapeutics (Suzhou) Co., Ltd. (China) | Co sponsors trial with | 2 |
| University of Southampton | Co sponsors trial with | 1 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 1 |
| Boehringer Ingelheim (Germany) | Co sponsors trial with | 1 |
Showing 5 of 16 relationships.
Latest dated events (295)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-08-04 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-07 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 295 events.
CLIA clinical laboratory certificates (1)
| Lab | Certificate | Status |
|---|---|---|
| BIONTECH SE | Certificate of registration | Active |
Biomarker capability evidence (529)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| AFP | Trial sponsor | Named in trial inclusion criteria |
| AGA | Trial sponsor | Named in trial inclusion criteria |
| AGA | Trial sponsor | Named in trial inclusion criteria |
| AGA | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 529 evidence rows.
On Scientist.com
BioNTech SE is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, and biomarkers this organization publishes on.
Work with BioNTech AG on Scientist.com
For prices, more details, or to contact BioNTech AG, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.